|
Schirdewan博士的引述的參考文獻: 1 e: D! _' Z3 m8 b. O) n
4 s+ D/ Q" F$ U) O* _Camm, AJ et al., Remote control of implanted devices through Home Monitoring technology improves detection and clinical management of atrial fibrillation (透過Home Monitoring技術遠距控制植入式裝置可改進房顫的檢測和臨床管理), Europace, 11(1):54–61, 2009.
8 g1 D5 x2 V1 l1 f; E+ _" W9 c [. Y1 i Q. {
Daubert, JP et al., Inappropriate implantable cardioverter-defibrillator shocks in MADIT-II (MADIT-II中植入式心臟複律去顫器不合時宜的電擊), JACC, 51:1357–65, 2008
# Y" I9 {( d) }7 h/ _" } N. Q) G
Ricci, RP et al., Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) (心房顫動管理指南:歐洲心臟學會心房顫動管理工作小組), Europace, 12(10):1360–1420, 2010. 9 [9 o4 ]: e2 U4 ^
* e) E* S9 B" R8 l$ w r; i$ n2 Z
關於BIOTRONIK SE & Co. KG
6 K; O3 c! }. V9 }. h$ R1 ~" x) f2 f# ~
BIOTRONIK公司是世界領先的心血管醫療器材製造商之一,已售出數百萬台植入式裝置,全球員工超過5600位,業務遍及100多個國家。BIOTRONIK公司密切感知醫療界的脈動、評估醫生面臨的挑戰,從診斷、治療到患者管理,為患者醫護的所有階段提供最佳解決方案。BIOTRONIK公司及其不斷成功的理念在於品質、創新和可靠性,從而為全球醫生及其患者帶來信心和安心。進一步資訊請瀏覽: www.biotronik.com |
|